doi: 10.1161/hs1001.096003
(Stroke. 2001;32:2328.)
© 2001 American Heart Association, Inc.
Original Contributions |
Initial Experience of Platelet Glycoprotein IIb/IIIa Inhibition With Abciximab During Carotid Stenting
A Safe and Effective Adjunctive Therapy
From the Departments of and Cardiology (S.R.K., C.T.B., K.M.Z., D.L.B., O.M.W., M.J.S., J.S.Y.) and Vascular Surgery (E.G.B., K.O.), Cleveland Clinic Foundation, Cleveland, Ohio.
Correspondence to Jay S. Yadav, MD, Cleveland Clinic Foundation, 9500 Euclid Ave, F25, Cleveland, OH 44195. E-mail yadavj{at}ccf.org
Background and Purpose—— Abciximab has been shown to decrease periprocedural ischemic complications after coronary intervention. However, the adjunctive use of abciximab in carotid stenting has not been adequately studied. We sought to determine the efficacy and safety of abciximab in carotid stenting.
Methods—— Carotid stenting was performed in 151 consecutive patients determined to be at high surgical risk by a vascular surgeon. Of these, 128 consecutive patients received adjuvant therapy with abciximab (0.25 mg/kg bolus before the lesion was crossed with guidewire and 0.125 µg · kg-1 · min-1 infusion for 12 hours.). A heparin bolus of 50 U/kg was given, and activated clotting time was maintained between 250 to 300 seconds. All patients received aspirin and thienopyridine. Procedural and 30-day outcomes were compared between the control (n=23) and abciximab (n=128) groups.
Results—— The 2 groups had similar baseline characteristics. Procedural events were more frequent in the control group (8%; 1 major stroke and 1 neurological death) compared with the abciximab group (1.6%; 1 minor stroke and 1 retinal infarction; P=0.05). On 30-day follow-up, 1 patient presented with delayed intracranial hemorrhage in the abciximab group. There were no other major bleeding complications.
Conclusions—— Adjunctive use of abciximab for carotid stenting is safe with no increase in the risk of intracranial hemorrhage. This adjunctive therapy with potent glycoprotein IIb/IIIa inhibition may help to reduce periprocedural adverse events in patients undergoing carotid stenting.
Key Words: carotid arteries • platelets • stents
This article has been cited by other articles:
 |
|
 |
|
  A. J. Comerota and S. Thakur Antiplatelet Therapy for Vascular Interventions Perspectives in Vascular Surgery and Endovascular Therapy, March 1, 2008; 20(1): 28 - 35. [Abstract] [PDF]
|
|
|
|
 |
|
 E. R. Bates, C. J. D. Babb, D. E. Casey, C. U. Cates, G. R. Duckwiler, T. E. Feldman, W. A. Gray, K. Ouriel, E. D. Peterson, K. Rosenfield, et al. ACCF/SCAI/SVMB/SIR/ASITN 2007 Clinical Expert Consensus Document on Carotid Stenting: A Report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents (ACCF/SCAI/SVMB/SIR/ASITN Clinical Expert Consensus Document Committee on Carotid Stenting) Vascular Medicine, February 1, 2007; 12(1): 35 - 83. [PDF]
|
|
|
|
 |
|
 American Society of Interventional & Therapeutic N, Society for Cardiovascular Angiography and Interve, Society for Vascular Medicine and Biology, Society of Interventional Radiology, E. R. Bates, J. D. Babb, D. E. Casey Jr, C. U. Cates, G. R. Duckwiler, T. E. Feldman, et al. ACCF/SCAI/SVMB/SIR/ASITN 2007 Clinical Expert Consensus Document on Carotid Stenting: A Report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents (ACCF/SCAI/SVMB/SIR/ASITN Clinical Expert Consensus Document Committee on Carotid Stenting) J. Am. Coll. Cardiol., January 2, 2007; 49(1): 126 - 170. [Full Text] [PDF]
|
|
|
|
 |
|
 S. Chaturvedi and J. S. Yadav The Role of Antiplatelet Therapy in Carotid Stenting for Ischemic Stroke Prevention Stroke, June 1, 2006; 37(6): 1572 - 1577. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Steiner-Boker, M. Cejna, C. Nasel, E. Minar, and C. W. Kopp Successful Revascularization of Acute Carotid Stent Thrombosis by Facilitated Thrombolysis AJNR Am. J. Neuroradiol., September 1, 2004; 25(8): 1411 - 1413. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. B. Silva Jr. and W. T. Bohannon Use of Abciximab During Infrainguinal Peripheral Vascular Interventions: Initial Experience Perspectives in Vascular Surgery and Endovascular Therapy, June 1, 2004; 16(2): 153 - 154. [Abstract] [PDF]
|
|
|
|
|
|
J. E. Cohen, J. M. Gomori, and F. Umansky Endovascular Management of Spontaneous Bilateral Symptomatic Vertebral Artery Dissections AJNR Am. J. Neuroradiol., November 1, 2003; 24(10): 2052 - 2056. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. W. Kopp, S. Steiner, C. Nasel, D. Seidinger, I. Mlekusch, W. Lang, A. Bartok, R. Ahmadi, and E. Minar Abciximab Reduces Monocyte Tissue Factor in Carotid Angioplasty and Stenting Stroke, November 1, 2003; 34(11): 2560 - 2567. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. W. Stavropoulos, J. A. Solomon, M. C. Soulen, T. W. I. Clark, and R. D. Shlansky-Goldberg Use of Abciximab during Infrainguinal Peripheral Vascular Interventions: Initial Experience Radiology, June 1, 2003; 227(3): 657 - 661. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. G. Brott Angioplasty and Stenting Should Be Performed Only in the Setting of a Clinical Trial Stroke, October 1, 2002; 33(10): 2519 - 2520. [Full Text] [PDF]
|
|
|
|
 |
|
 S. Chaturvedi and R. Fessler Angioplasty and stenting for stroke prevention: Good questions that need answers Neurology, September 10, 2002; 59(5): 664 - 668. [Abstract] [Full Text] [PDF]
|
|